01—Abstract
Summary
Summary of the 10-K filed March 27, 2002. Cited figures are marked; the original filing is the authoritative source.
Charles River Laboratories International, Inc. reported net sales of $465.6 milliona for the fiscal year ended December 29, 2001, up $159.0 million, or 51.9%, from $306.6 million in 2000.
The increase was driven largely by the first-quarter 2001 acquisitions of Pathology Associates International Corporation (PAI) and Primedica Corporation, which contributed $118.0 millionb of sales. On a pro forma basis, sales increased 15.0%. Biomedical products and services grew to 58% of 2001 net sales, while research models, the company's historical core business, accounted for 42%.
Operating income rose to $90.3 millionc from $65.1 million, and net income was $35.4 million, compared with a net loss of $11.2 million in 2000. Results include a $5.2 million after-tax extraordinary loss on debt repayment. Cash flow and the balance sheet improved meaningfully.
Net cash provided by operating activities was $71.3 milliond, cash and cash equivalents were $58.3 million at year-end, and total debt was $156.8 million, down from $202.9 million. Shareholders' equity rose to $289.5 million. The company completed two 2001 follow-on stock offerings with combined net proceeds of $116.7 million, which were used largely to repay debt and fund acquisitions.
Subsequent to year-end, the company issued $185.0 million par value of 3.5% senior convertible debentures due 2022 (including the additional $10.0 million option exercised February 11, 2002), with a conversion price of $38.87, and used part of the proceeds to tender for $79.7 million par value of its 13.5% senior subordinated notes at a premium of approximately 29.5%. The filing also flags risks including contamination in animal populations, changes to the Animal Welfare Act, competition, dependence on pharmaceutical and biotechnology customer spending, and the possibility that the Internal Revenue Service could challenge the tax benefits tied to the 1999 recapitalization.
02—Key points
Key Highlights
- Net sales of $465.6 million in 2001, up 51.9% from $306.6 million; pro forma sales increased 15.0%.
- Biomedical products and services represented 58% of 2001 net sales, with net sales of $268.1 million, up 108.5%, largely from the PAI and Primedica acquisitions.
- Research models net sales were $197.5 million, up 11.0%, and represented 42% of 2001 net sales.
- Operating income increased to $90.3 million from $65.1 million; net income was $35.4 million versus a net loss of $11.2 million in 2000.
- Net cash provided by operating activities was $71.3 million, up from $33.8 million, and year-end cash was $58.3 million.
- Total debt fell to $156.8 million from $202.9 million, and shareholders' equity increased to $289.5 million.
- In early 2002, the company issued $185.0 million of 3.5% senior convertible debentures due 2022 and tendered for $79.7 million of its 13.5% senior subordinated notes.
03—Questions
Frequently Asked Questions
What drove the large increase in 2001 revenue?
Net sales rose $159.0 million, or 51.9%, to $465.6 million. Biomedical products and services grew $139.5 million, or 108.5%, mainly because of the PAI and Primedica acquisitions made in the first quarter of 2001, which contributed $118.0 million of sales. Research models sales increased 11.0% to $197.5 million.
How did profitability change in 2001?
Operating income increased $25.2 million, or 38.7%, to $90.3 million, and operating margin was 19.4% of net sales versus 21.2% in 2000. The company reported net income of $35.4 million, compared with a net loss of $11.2 million in 2000. The effective tax rate was 39.0%, and the 2001 results included an extraordinary loss of $5.2 million net of tax from debt repayments.
How is the company's debt and capital structure changing?
Total debt declined to $156.8 million at year-end 2001 from $202.9 million. In January and February 2002, the company issued $185.0 million of 3.5% senior convertible debentures due 2022, convertible at $38.87 per share, and used part of the proceeds to tender for $79.7 million par value of its 13.5% senior subordinated notes at a premium of approximately 29.5%. The company is a holding company and relies on dividends from its subsidiary to meet cash needs.
What are the main risks identified in the filing?
Key risks include the success of acquisitions and their integration, contamination in animal populations that can cause inventory loss and reduced sales, customer concentration in the pharmaceutical and biotechnology industries, and the potential for alternative non-animal testing methods to reduce demand. Other risks include possible changes to the Animal Welfare Act, competition, foreign currency exposure (the company does not hedge), and a possible Internal Revenue Service challenge that could require writing off a deferred tax asset tied to the 1999 recapitalization. The company reported a deferred tax asset of $87.8 million in non-current assets.
How concentrated is the customer base?
The company states that its top 20 global commercial customers represented about 30.0% of 2001 net sales, and no individual customer accounted for more than 3.0% of net sales. The customer base includes the 10 largest pharmaceutical companies by 2001 revenues, and all of the company's top 20 customers in 1990 remain customers.
04—Continue